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ABSTRACT 
Background: It is estimated that one-third of women will experience abnormal menstrual 
bleeding. The majority of these cases are not due to cancer or pregnancy complications, and as a 
result, women are faced with a variety of treatment alternatives, the selection from which is 
largely dependent on personal preferences for care rather than clinical outcomes. 
Objective: This randomized trial was designed to evaluate a preference elicitation tool to 
promote physician-patient collaborative decision-making for treatment of abnormal uterine 
bleeding (AUB).  
Methods: Adaptive conjoint analysis (ACA) was used to create a preference-elicitation tool in 
English and in Spanish. Women with AUB were randomly assigned to ACA or usual 
counseling at the initial clinic visit at four clinics (three in Indianapolis, IN and one in Southern 
Pines, NC). The ACA tool elicited preferences across eight attributes: treatment efficacy; sexual 
function; medical care; cost; fertility; frequency of medication use; permanence; and recovery 
time. T-tests were used to compare differences in the primary outcomes of decision regret and 
treatment satisfaction at the follow-up visit.  The study was designed to have 80% power to 
detect significant differences between groups for the primary outcomes of regret and 
satisfaction. 
Results: Women were enrolled in the study between September 2009 and March 2012 in four 
clinics (three in Indiana and one in North Carolina). 183 participants were randomized to ACA 
and 191 to usual counseling. Overall, mean (SD) treatment satisfaction was high at 35.71 (9.72) 
(scale of 0-44), and decision regret was low at 25.9 (21.0) (scale of 0-100), creating ceiling 
effects for the selected outcome variables; there were no significant differences between the 
ACA and control group at the follow up assessment. There was a strong inverse relationship 
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between age and decision regret (p=0.007). Exploratory subgroup analysis in the youngest 
quartile comprising 64 women age 19-35 showed a statistically non-significant difference in 
mean regret scores for the ACA group versus usual counseling (24.6 vs. 34.6, respectively, p = 
0.08).  
Conclusions: A preference-elicitation tool at the initial consultation visit did not reduce 
decision regret or improve treatment satisfaction among patients with AUB; however, there is a 
need for additional research to further understand this tool’s potential role in promoting 
collaborative decision making, which may be particularly important among younger women. 
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Key points for decision makers 
• Individuals seeking care are empowered and expected to engage as active 
participants; however, there is no standard approach to elicit a patient’s preference for 
treatment alternatives.   
• Adaptive conjoint analysis is becoming more common in decision analyses, but has 
not often been used as a tool to facilitate shared decision making. 
• This randomized trial found that using ACA was well accepted and was easily 
implemented into routine clinical practice but did not demonstrate impact on future 
treatment satisfaction or decision regret. 
• Future studies should assess the impact of adaptive conjoint analysis as a preference 
elicitation tool on more proximal outcomes. 
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INTRODUCTION 
It is estimated that approximately 30% of women will experience heavy menstrual bleeding.(1) 
Abnormal uterine bleeding (AUB) is defined as “bleeding from the uterine corpus that is 
abnormal in duration, volume, and/or frequency” and may be acute or chronic (6 months 
duration or more).(2) Up to one-third of all outpatient gynecology clinic visits are due to some 
form of abnormal uterine bleeding (AUB).(3) While this condition is not associated with serious 
adverse events or mortality, the impact of this condition can be considerable on the patient and 
others, impacting interpersonal relationships, the ability to engage in social and work activities, 
and health-care related costs and quality of life.(4, 5)  The etiology of AUB is varied and 
classification systems have been developed to understand the causes of abnormal bleeding in 
the nongravid woman (6). AUB treatment alternatives include hormonal therapy (i.e. oral 
contraceptives, progestins, other hormonal treatments), the use of an internal uterine device 
(IUDs), or the slightly more invasive procedure of endometrial ablation (for those who no 
longer desire fertility), or inpatient surgical procedures such as hysterectomy. (A table 
summarizing the most common treatment options is provided as Electronic Supplementary 
Material.) These therapeutic options are effective across a range of underlying etiologies 
including ovarian and endometrial dysfunction, small leiomyomata and polyps, and initial 
treatment for bleeding associated with inherited coagulopathy. In some cases, such as large 
polyps or cancerous masses, the patient may require surgical intervention. However, for the 
majority of cases, no clear single option is clinically preferred despite the heterogeneity of the 
condition (e.g. abnormal ovulation patterns or a disorder of the endometrium both are treated in 
a similar manner). Therefore, the choice between treatment options is often tailored to patient 
preference for surgical versus medical management, individual desire to maintain fertility, the 
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risks and benefits, as well as the costs and time associated with the various treatment options. 
As a result, the patient consult can be time consuming to enable informed shared patient-
provider decision making for the preferred treatment for the patient’s AUB.  
 
Patient-centered models of care are becoming the norm, whereby individuals seeking care are 
empowered to engage as active participants in their care, and to receive treatments and services 
that reflect their own preferences, desires and needs. However, there is no standard approach to 
elicit a patient’s preference for treatment alternatives.  In the setting of AUB, ensuring patient-
centered decision making can be difficult given the number of options for care and numerous 
trade-offs that a patient must make in the selection of treatment. If the physician could elicit 
patient preferences for the key attributes of treatment alternatives, this could result in efficient 
patient counseling and subsequent care that is more concordant with patient needs and 
preferences, which is the ultimate goal of shared decision-making.  
 
This study was designed to develop and test the use of adaptive conjoint analysis (ACA)(4-9) to 
elicit those individual patient preferences as part of routine clinical care for women diagnosed 
with AUB. ACA is able to elicit such a summary of patient preferences across a variety of 
attributes for a wide range of treatment options. ACA works in several phases. First, it asks 
respondents to rank their preferences across the list of attributes of available treatment options. 
Then, respondents are sequentially presented with the ‘best’ and ‘worst’ scenarios (based on 
their responses to the ranking exercise) of those attributes, where they are able to rate the 
choices on an interval scale for levels of importance. Then, attributes are paired and respondents 
must make choices on a 9-point scale which quantifies how much more one option is preferred 
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to another. Lastly, the participant is presented a series of treatment options combining specific 
attributes according to her individual preferences, and through an iterative and adaptive process, 
determines the optimal set of attributes for treatment.(7) As patient-centered care has grown in 
importance in clinical centers across the U.S., ACA has been used to assist patients and their 
providers choose among treatment alternatives in a variety of disease settings, such as 
osteoporosis treatment;(8) knee pain treatment;(9) surgery for colorectal cancer liver 
metastases;(10) preoperative radiotherapy in rectal cancer;(11) and the choice of care for 
primary prophylaxis of variceal hemorrhage.(12)  
 
In this study of women with AUB, it was hypothesized that the elicitation and sharing of patient 
preferences between patient and provider would be associated with greater satisfaction with care 
and with less decision regret than for patients did not complete the ACA exercise. 
 
MATERIALS AND METHODS 
Sawtooth Software SSI Web 6.4.4 was used to develop an ACA survey in English and in 
Spanish to be administered at the time of the patient’s initial clinic visit. The treatment attributes 
were developed based on the attributes of treatment options available for AUB (i.e., ablation, 
hysterectomy, IUD, oral hormone medications). Levels of each attribute were also identified 
based on clinical characteristics of treatment alternatives.  The attribute descriptions were 
presented in a study of eight women who met the eligibility criteria for the randomized study. 
These participants completed the draft survey and provided qualitative feedback on its 
presentation, treatment attributes, and the wording of each attribute and levels of each attribute 
(13). The ACA survey was iteratively revised and finalized based on the results of this pilot 
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testing study. The final ACA survey included eight attributes of the various treatment 
alternatives that could be possible choices for all eligible participants. These attributes included: 
treatment efficacy; sexual function; medical versus surgical care; cost; fertility; frequency of 
medication use; permanence; and recovery time. The study attributes and levels are provided in 
Table 1. The ACA survey was designed so the irrelevant combinations of attribute levels were 
excluded from the survey (e.g. a treatment choice with daily pills and hospital stay would not be 
clinically possible and could not be paired). All study methods and procedures for the pilot 
testing and the randomized trial were approved by the Indiana University Institutional Review 
Board prior to initiation of any study activities. 
 
Between September 2009 and March 2012, patients presenting to participating gynecology 
clinics (Southern Pines Women’s Health Center, Southern Pines NC; Primary Care Clinic of 
Wishard Hospital, Cottage Corner Clinic, or Coleman Center for Women, Indianapolis IN) were 
enrolled to the study prior to meeting with the physician. Potentially eligible patients were 
screened by the research staff member based on reasons for the clinic visit, and were verified by 
the treating physician. Potentially eligible patients were approached by a member of the 
research team prior to meeting with the physician to discuss potential treatment options. The 
research staff member introduced the study using a core script and after making final eligibility 
determination based on an eligibility questionnaire, obtained informed consent among interested 
patients. Factors evaluated for eligibility required that patients were those with AUB that had 
not yet been treated for their bleeding, had not previously been diagnosed or treated for AUB, 
did not have cancer within the past two years, were not pregnant, and could not have AUB due 
to a serious pelvic pathology (e.g. current or prior cancer) or due to medication use. 
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Additionally, eligible patients were age 18 or older and were potential candidates for either 
surgical or medical treatment. The diagnosis of AUB, the recommendation for treatment 
(including the requirement that patients were eligible for either medical or surgical 
interventions) were required to be verified by the treating physician for final study eligibility 
prior to randomization to avoid bias due to post-randomization eligibility exclusions. 
 
After providing written informed consent, study participants completed a demographics 
questionnaire and the Symptom Severity Scale of the validated Uterine Fibroid Symptom 
Quality of Life (UFS-QOL) survey.(14) Patients were then centrally randomized via a simple 
1:1 randomization method using SPSS random number generation. Randomization was 
stratified by clinic site, and patients were assigned to either the ACA survey or to usual 
counseling. Study staff and patients were blinded to the group allocation until after obtaining 
informed consent and completing the baseline surveys to minimize any potential bias in study 
enrollment. Those randomized to the ACA completed the survey prior to meeting with the 
physician for discussion of treatment alternatives, whereas patients randomized to usual 
counseling proceeded to meet with their physician for this discussion after completion of the 
baseline surveys. The ACA was presented to participants randomized to that group via a 
touchscreen computer. Participants in the ACA group answered a series of preference-based 
questions to elicit their values across each of the eight treatment attributes and through various 
combinations of those attributes. Immediately following completion of the ACA survey, the 
printed results were provided to the patient and the physician for use during the patient consult 
(Figure 1) along with a guide to interpretation of the results. Physicians were not blinded to 
those randomized to ACA for obvious reasons, but were not informed as to which of their 
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patients were enrolled to the study in the usual counseling group so as to not bias the discussion 
among the comparison group of study participants. 
 
Approximately six weeks following the initial study visit, study participants were mailed two 
surveys to evaluate the primary study endpoints of treatment satisfaction and decision regret—
the Functional Assessment of Chronic Illness Therapy-Treatment Satisfaction-Patient Scale 
(FACT-TS-PS) and the Decision Regret Scale. Four subscales (interpersonal, decision making, 
trust and overall subscale) of the validated FACIT-TS-PS were used.(15) The Decision Regret 
Scale is a validated instrument that measures health care decision regret.(16) In cases of 
nonresponse to the initial mailing, reminder phone calls and up to three additional mailed copies 
of the surveys were sent prior to determining a patient to be lost to follow up. Participants were 
instructed to wait to complete the survey if treatment had not yet been received.  
 
Sample size 
It was determined that a sample size of 71 patients per group would allow the detection of a 10-
point mean difference on the Decision Regret Scale, with 80% power and a 0.05 level of 
significance, assuming a standard deviation of 21. A total sample size of 142 was therefore 
needed to have sufficient power to assess decision regret. The FACIT-TS-PS questionnaire 
items were combined into a continuous measure for overall satisfaction(15). A total of 286 
participants were needed for 80% adequate power to detect a 7-point difference for two-tailed 
tests at the 0.05 level of significance. The study was designed to enroll 380 patients to account 
for a 20% anticipated non-response rate to have sufficient power for each endpoint analysis. 
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Data analysis 
Data were analyzed using SPSS 15.0. All analyses were performed as intent-to-treat. 
Descriptive statistics were used to understand the demographic and clinical characteristics as 
well as the baseline survey responses, treatment choices and preference values of the overall 
study population. An individual score for the baseline UFS-QOL Symptom Severity Scale was 
calculated by summing the eight items. Higher scores reflect greater symptom severity, whereas 
lower scores indicate minimal symptom severity. Groups were compared using t-tests, chi-
square analyses, and analysis of variance (ANOVA). In the case of a significant omnibus F-test 
in ANOVA, Tukey’s post-hoc tests were conducted to control for multiple comparisons 
between subgroups. Exploratory analyses, which did not control for any potential confounding, 
were conducted to explore relationships in demographic subgroups for the purpose of 
hypothesis generation. Paired t-tests were used for the primary outcome analysis of decision 
regret and satisfaction by study group (ACA versus usual counseling). Regret scale scores range 
from 0 (no regret) to 100 (high regret). Scores for each item on the FACIT-TS-PS are summed 
for a total satisfaction score.. 
 
RESULTS 
Three hundred and eighty-six women provided informed consent and enrolled in the study. Of 
these, seven were found to be ineligible and were not included in the study and five changed 
their mind about participating; resulting in a total of 374 eligible participants. Of these, 183 
were randomized to the ACA survey and 191 were randomized to usual counseling (Figure 2). 
Eighty-three (22.2%) participants did not return the final surveys (23% in the ACA arm versus 
21.5% in the control arm, p=0.80, Table 2) and were considered lost to follow up; study data 
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were complete for 291 eligible participants. There were no significant differences in the 
characteristics of patients lost to follow up versus those with complete data. Time to follow up 
was on average, 62 days, with a wide range of time from treatment selection to survey 
completion (38-177 days). 
 
There were no differences in baseline characteristics or symptom severity between study groups 
(Table 2). There were no significant differences in symptom severity by race/ethnicity, 
insurance status, marital status, or education and there was no correlation between total 
symptom severity score and age (p=0.63).  
 
Treatment selection 
Two hundred and eighty-five participants provided information on the treatment they had 
selected for their AUB (Table 3). Differences in treatment choice between those randomized to 
ACA or usual counseling were small in magnitude and not statistically significant. The most 
common treatment choice was prescription medications such as oral contraceptives or hormone 
injection (n=123, 43.2%), followed by indecision (n=55, 19.3%) and hysterectomy (n=30, 
10.5%). There were significant differences in treatment choice by both education (p=0.02) and 
racial/ethnic group (p=0.007), but not by age, or marital or insurance status. African American 
patients were more likely undecided about treatment at the time of follow up, and White 
patients were less likely than expected to be undecided about treatment at the time of follow up. 
Conversely, White participants were more likely to select prescription medications than African 
American patients. There were no differences between these groups with regard to the selection 
of IUD, ablation or hysterectomy. Patients with a college degree or more were more likely to 
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select prescription medication for care than those with a high school or some college education. 
There were no other differences by subgroup of educational attainment. There were no 
differences in treatment selection based on symptom severity score. 
 
Patient Preferences 
The preferences of patients randomized to ACA are presented in Table 4. The most important 
treatment attributes to study participants were treatment efficacy and the desire to minimize any 
impact on sexual function. The attributes that had the least value to participants in their decision 
making were if the treatment choice was permanent or if the treatment required taking pills.  
 
There were a number of significant differences in treatment preferences based on the pre-
planned, exploratory analyses of demographic characteristics. Insurance status was significantly 
related to preference for cost of treatment (p=0.017), with the privately insured having a 
significantly lower value associated with costs than those supported by Medicaid or other 
subsidized insurance (p=0.045, adjusted for multiple comparisons). The importance of treatment 
efficacy (p=0.033) and the need to take pills (p=0.025) was significantly different by 
racial/ethnic group. At the subgroup level, treatment efficacy was no longer statistically 
significant when adjusting for multiple comparisons, however, Hispanic participants were 
significantly less likely to want to take pills every day as compared to African American 
(p=0.026) or White (p=0.014) participants (ANOVA post-hoc tests adjusted for multiple 
comparisons). Cost was also significantly different by education level (p=0.005), however, this 
was only significant at the subgroup level for those with only some high school education, who 
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placed a significantly higher value on the cost of treatment than women with a college 
education (p=0.006, adjusted for multiple comparisons). 
 
There were significant differences by age for preferences related to treatment efficacy (p=0.01), 
sexual function (p=0.05) and the impact on fertility (p<0.001) (ANOVA, by quartiles: 19-35; 
35.1-41.8; 41.9-46.4; >46.4). Controlling for multiple comparisons, the second age quartile was 
less likely to place importance on treatment efficacy than the third quartile (p=0.008). Sexual 
function was significantly less important to the oldest quartile than the third quartile (p=0.04), 
and fertility was significantly more important to the youngest quartile than the second 
(p=0.047), third (p<0.001) and fourth quartile (p<0.001).  Recovery time in post hoc tests was 
found to be was more important to the youngest quartile compared to the oldest quartile 
(p=0.04). There was no significant relationship between symptom severity and treatment 
preferences. 
 
Post-hoc descriptive analyses explored the preferences of patients across the eight attributes of 
treatment options to understand whether the strength of values and preferences were consistent 
with treatment choice. Due to the small sample size across multiple treatment choices, the top 
four treatments selected by patients in the study (oral medications, IUD, ablation and 
hysterectomy) were used to explore the strength of preferences by treatment selected (Figure 3). 
Lower scores represent that the factor was of little value, whereas higher scores meant that the 
attribute was very important. While no significance testing could be conducted due to the small 
sample size, the attributes appear to be in accordance with what one might expect. For example, 
women who selected oral medications (Group A in Figure 3) valued their fertility, women who 
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selected hysterectomy (Group D in Figure 3) did not want to have to continue to visit their 
doctor regularly (a low value meant that this did not matter). Women selecting ablation or 
hysterectomy (Groups C and D) valued a treatment that worked right the first time (high 
efficacy). However, caution should be taken when interpreting these data and variability around 
each of the point estimates, as the varied confidence intervals are largely due to the small 
sample size of each group (other than the oral medication group, which was approximately half 
of the overall respondent group for this post-hoc analysis). 
 
Satisfaction with Care 
Satisfaction with care for the study population was high, with a mean score of 35.74 (SD: 9.72), 
out of a possible range of 0 to 44. Patients in the ACA group had equivalent satisfaction with 
care scores as those randomized to usual counseling (35.72, 95% CI: 34.0-37.4 versus 35.75, 
95% CI: 34.2-37.3, p=0.98). There were also no differences in satisfaction by demographic 
characteristics or treatment selected. 
 
Decision Regret 
The average decision regret score in the study population was 25.9 (SD: 21.0). There was no 
difference between treatment regret by study group, with those randomized to ACA having a 
mean score of 25.1 (95% CI: 21.7-28.5) versus 26.7 (95% CI: 22.9-30.4) for usual counseling 
(p=0.54). There were no differences with decision regret scores by education, race/ethnicity, 
marital or insurance status. There was a highly significant inverse relationship between age and 
decision regret (p=0.007), with younger age associated with greater regret. There were 
significant differences in decision regret by the choice of treatment (p=0.01). Women who 
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underwent a hysterectomy had the lowest regret (mean decision regret score of 14.4), which was 
significantly different than those who received prescription medications (mean decision regret 
28.0) or women who remained undecided about treatment (mean decision regret 31.8). There 
were no other differences in regret by treatment selected.  
 
In the youngest quartile of patients (age 19-35) a 10-point difference in mean regret scores was 
observed for the ACA group versus usual counseling in the hypothesized direction (24.6 vs. 
34.6, respectively, p = 0.08). Although this difference was not statistically significant, the small 
number of patients in this quartile (n=64) increases the likelihood of a Type II error. 
 
DISCUSSION 
There are several potential reasons why this randomized trial of a preference elicitation tool in a 
general sample of patients referred for AUB management did not detect differences in decision 
regret or satisfaction. Overall, regret was relatively low and satisfaction with care was high, 
suggesting that there was very little room for improvement in this population on the endpoints 
selected. In retrospect, while the primary aims were intended to assess satisfaction with the 
treatment selected, decisions were often not acted upon for many weeks following the 
counseling session due to various factors such as scheduling or the need for further tests. 
Therefore, the time point selected for follow up (e.g. 6 weeks after the study visit) is likely too 
far removed from the decision making process to accurately assess any remaining outcomes 
associated with the initial clinic visit. Despite the fact that the primary aims were not achieved 
in this study, there is considerable room for improved study designs and interventions using 
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ACA in the setting of AUB.  For these reasons we believe that future studies will provide 
evidence supporting the use of ACA to support the treatment decision making process. 
 
The use of ACA for preference elicitation is relatively new. In contradistinction to provision of 
information about the alternatives, ACA uses a structured protocol in which patients are 
prompted to consider and quantify what matters to them, and by how much. The resultant 
preference information allows both the patient and provider to know how the patient prioritizes 
the various attributes of treatment alternatives and may then be used as part of a decision 
support process, rather than being a decision aid in and of itself.  Furthermore, the preference 
elicitation instrument is easily incorporated into clinical practice, as it is delivered via an 
internet-based survey and can be completed by patients in 15-20 minutes while waiting for their 
clinic appointment. Future studies should assess more proximal outcomes (e.g. satisfaction with 
the decision making process, not just the outcomes) among both patients and providers, and 
should keep records of the clinic time needed for counseling with and without the ACA tool, as 
these may prove to be meaningful endpoints of interest. 
 
In addition to these lessons learned, additional information was obtained regarding the AUB 
population. The treatment choice analyses in this study found that prescription medications 
were the most commonly selected treatment alternative for AUB. While the results of the 
demographic subgroup analyses can only be considered a hypothesis generating, this was 
significantly higher among White women as compared to African American women who more 
often chose hysterectomy. Taking medications each day was also significantly less desirable to 
Hispanic women. The factors contributing to these different preferences is something that 
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should be studied in the future, and may help explain barriers or promoters against or for 
particular recommendations for care of AUB.  
 
Hysterectomy as a treatment choice was associated with the lowest level of decision regret. This 
is consistent with improved satisfaction and less regret found in other populations, such as 
BRCA mutation carriers, who elect prophylactic surgery to reduce cancer risk.(17) It is possible 
that a decision such as hysterectomy, which cannot be reversed, was preceded with more 
thoughtful decision making. It is also possible that simply due to the selection of an irreversible 
option, patients have no other choice moving forward, while women who are being treated with 
hormone therapy may continue to wonder if surgery will be needed in the future. Future 
research should seek understand these factors to learn how to reduce decision regret for all 
treatment choices to levels found among women who underwent hysterectomy. 
 
This study has several strengths.  Participants represented a broad cross-section of women 
evaluating treatment options for AUB.  The randomized, longitudinal design allowed for the 
comparison of ACA use apart from potential confounders and to determine its impact six weeks 
after the initial consultation. The use of validated measures for decision regret and treatment 
satisfaction allowed for greater precision for detecting a difference in outcomes.  With 374 
randomized participants, and final outcomes data available for 277 and 270 for satisfaction and 
decision regret, respectively, this study had ample statistical power to find a clinically important 
difference in both variables. 
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There are also several limitations.  We recruited a diagnostic cross-section of women presenting 
to participating clinics with AUB of varied etiologies and may not be generalizable to specific 
diagnostic subgroups of AUB. Since risk factors for decision regret or treatment dissatisfaction 
in the setting of AUB were not established in other studies, study recruitment could not be 
limited to subsets of women at greatest risk. This resulted in a lack of statistical power to 
identify subgroups, such as younger women, who could be hypothesized to benefit most from 
the ACA.  In addition, the ACA results were made available to physicians but did not require 
any documentation to verify their use of this tool.  Therefore, there is incomplete knowledge of 
the true differences in counseling between the ACA and usual counseling groups that should be 
pursued in future research using ACA for AUB. Additionally, satisfaction and regret are 
multifactorial constructs that are influenced by many factors. Future work that wishes to retain 
the same study endpoints as in the present randomized trial may fist wish to explore the aspects 
of counseling and care that are associated with patient satisfaction and regret in the setting of 
AUB.   
 
This study provides hypothesis generating data suggesting that higher decision regret may occur 
among the youngest quartile of study participants. While the regret score did not reach 
statistical significance by ACA or usual counseling (p=0.08), there were only 64 patients in this 
group and Type II error was likely. This is an intriguing finding, and suggests that future studies 
may wish to target those at greatest risk of decision regret who may potentially benefit from an 
intervention such as ACA. Age has been a contributing factor for decision regret in other 
conditions;(16,17) however, little data exist for women with AUB. Young patients may 
represent a population that should receive additional care in counseling for treatment decision 
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making to reduce future regret. Further research should also address the relationship or possible 
clustering of preferences as well as the relationship between the strength of the preference and a 
patient’s treatment decisions, as the current study was not powered or designed to assess these 
outcomes. 
 
In conclusion, a preference-elicitation tool developed using ACA did not reduce decision regret 
or improve treatment satisfaction among patients with AUB presenting for an initial 
consultation visit.  However, many lessons were learned about the study population, treatment 
selection, and approaches for future study design. Additionally, there is promise in the use of an 
approach such as ACA to aid the counseling process in settings such as AUB where treatment 
selection is largely based on patient preferences for care. There is a need for future work to 
continue to assess the value of this approach using study designs and considerations as 
discussed above. 
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Figure legends 
Figure 1. Example patient/provider printout showing individual patient preference results from 
the adaptive conjoint analysis (ACA) survey regarding attributes of treatment for abnormal 
uterine bleeding (AUB) 
 
 
Figure 2. CONSORT flow diagram 
 
Figure 3. Preferences of treatment attributes (mean and 95% confidence interval) by the four 
most common treatments selected: A-oral medications; B-intrauterine device (IUD); C-ablation; 
D-hysterectomy (n=90)  
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Table 1. Attributes and levels used in the adaptive conjoint analysis survey 
Attribute Levels Descriptor 
Treatment success 3 How effective is the treatment 
Sexual function 3 What is the impact on sexual function 
Medical care 3 Where does the treatment take place 
Cost 4 Cost of the treatment 
Fertility 4 What is the impact on fertility 
Oral medications 3 Frequency of oral medication use 
Permanence 2 Can the treatment outcome be reversed or is it permanent 
Recovery time 3 What is the recovery time 
 
Table 2. Demographic and clinical characteristics 
 Adaptive 
Conjoint 
Analysis (n=183) 
Usual counseling 
(n=191) 
p-value 
Age – mean (SD) 41.2 (7.9) 40.8 (8.3) 0.63 
Education – n (%) 
8th grade or less 4 (2.1%) 4 (2.1%) 
0.75 
Some high school 22 (12.0%) 31 (16.2%) 
High school graduate/GED 63 (34.4%) 62 (32.5%) 
Some college/technical school 53 (29.0%) 58 (30.4%) 
College graduate 41 (22.4%) 36 (18.8%) 
Marital status – n (%)  
Married/cohabitating 82 (44.8%) 88 (49.2%) 
0.74 
Divorced/separated 51 (27.9%) 45 (23.6%) 
Widowed 3 (1.6%) 5 (2.6%) 
Never married 47 (25.7%) 53 (27.7%) 
Race/Ethnicity – n (%)  
White, non-Hispanic 86 (47.0%) 94 (49.2%) 
0.57 African American 85 (46.4%) 80 (41.9%) 
Hispanic 8 (4.4%) 11 (5.8%) 
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Native American 3 (1.6%) 4 (2.1%) 
Asian 0 (0%) 2 (1.0%) 
Insurance status 
Insured (Private) 141 (77.0%) 153 (80.1%) 
0.68 Insured (Public/Subsidized) 34 (18.6%) 29 (15.2%) 
Uninsured 8 (4.4%) 9 (4.7%) 
Symptom burden – mean (SD)a 29.79 (6.40) 29.76 (6.47) 0.97 
Days to follow up assessment – 
mean (SD) 
60.1 (21.4) 64.3 (24.9) 0.16 
Lost to follow up - n (%) 42 (23.0%) 41 (21.5%) 0.80 
a USF-QOL Symptom Severity Scale, possible range 8-40 
Table 3. Treatment choice, by study group* 
Treatment choice Adaptive 
Conjoint Analysis 
(n=140) 
Usual counseling 
(n=145) 
Prescription medication 63 (45%) 60 (41.4%) 
Intrauterine  device (IUD) 6 (4.3%) 5 (3.4%) 
Endometrial ablation 14 (10.0%) 9 (6.3%) 
Hysterectomy 13 (9.3%) 17 (11.7%) 
Not decided 29 (20.7%) 26 (17.9%) 
Declined treatment 8 (5.7%) 12 (8.3%) 
Other 7 (5.0%) 16 (11.0%) 
* None of the choices were significantly different between groups 
  
27 
 
Table 4. Mean attribute importance values (n=183) 
Attribute Mean (SD) 
(Possible range = 0-~35) 
95% CI 
Treatment efficacy 15.6 (5.8) 14.9-16.5 
Impact on sexual function 13.7 (6.1) 12.9-14.7 
Cost 13.7 (5.3) 13.0-14.5 
Need for additional medical 
visits 
13.3 (5.5) 12.5-14.1 
Impact on fertility 12.2 (5.8) 11.3-13.0 
Recovery time 11.2 (4.8) 10.5-11.9 
Need to take pills 10.2 (5.5) 9.4-11.0 
Permanence of treatment choice 10.0 (5.5) 9.2-10.8 
 
 
 
 
 
 
